📣 VC round data is live. Check it out!

Pyridam Farma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Pyridam Farma and similar public comparables like Hamlet BioPharma, Mersana Therapeutics, Satellos Bioscience, Orthocell and more.

Pyridam Farma Overview

About Pyridam Farma

PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical Products and Toll Manufacturing Services; and Medical Device Products. The company derives maximum revenue from Pharmaceutical Products and Toll Manufacturing Services. The company's products include consumer health, Derma, prescription, and biomedilab.


Founded

1976

HQ

Indonesia

Employees

1.4K

Website

pyfa.co.id

Financials (FY)

Revenue: $155M
EBITDA: ($6M)

EV

$410M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Pyridam Farma Financials

Pyridam Farma reported last fiscal year revenue of $155M and negative EBITDA of ($6M).

In the same fiscal year, Pyridam Farma generated $33M in gross profit, ($6M) in EBITDA losses, and had net loss of ($21M).


Pyridam Farma P&L

In the most recent fiscal year, Pyridam Farma reported revenue of $155M and EBITDA of ($6M).

Pyridam Farma is unprofitable as of last fiscal year, with gross margin of 21%, EBITDA margin of (4%), and net margin of (14%).

See analyst estimates for Pyridam Farma
Last FY202320242025202620272028
Revenue$155M$39M$108M$155M
Gross Profit$33M$17M$30M$33M
Gross Margin21%42%28%21%
EBITDA($6M)$887K($2M)($6M)
EBITDA Margin(4%)2%(2%)(4%)
EBIT Margin(6%)(1%)(2%)(6%)
Net Profit($21M)($5M)($18M)($21M)
Net Margin(14%)(12%)(17%)(14%)
Net Debt$198M---

Financial data powered by Morningstar, Inc.

Pyridam Farma Stock Performance

Pyridam Farma has current market cap of $145M, and enterprise value of $410M.

Market Cap Evolution


Pyridam Farma's stock price is $0.01.

Pyridam Farma share price decreased by 1.1% in the last 30 days, and by 8.2% in the last year.

See more trading valuation data for Pyridam Farma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$410M$145M-1.1%-1.1%-28.8%-8.2%$-0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Pyridam Farma Valuation Multiples

Pyridam Farma trades at 2.7x EV/Revenue multiple, and (63.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Pyridam Farma

Pyridam Farma Financial Valuation Multiples

As of June 3, 2026, Pyridam Farma has market cap of $145M and EV of $410M.

Pyridam Farma has a P/E ratio of (6.8x).

Last FY202320242025202620272028
EV/Revenue2.7x10.4x3.8x2.7x
EV/EBITDA(63.1x)n/m(238.4x)(63.1x)
EV/EBIT(43.4x)n/mn/m(43.4x)
EV/Gross Profit12.6x24.8x13.7x12.6x
P/E(6.8x)(30.3x)(7.8x)(6.8x)
EV/FCF(13.7x)(57.4x)(26.5x)(13.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Pyridam Farma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Pyridam Farma Margins & Growth Rates

In the most recent fiscal year, Pyridam Farma reported gross margin of 21%, EBITDA margin of (4%), and net margin of (14%).

See estimated margins and future growth rates for Pyridam Farma

Pyridam Farma Margins

Last FY20242025202720282029
Gross Margin21%28%21%
EBITDA Margin(4%)(2%)(4%)
EBIT Margin(6%)(2%)(6%)
Net Margin(14%)(17%)(14%)
FCF Margin(19%)(14%)(19%)

Pyridam Farma Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth174%44%
Gross Profit Growth82%9%
EBITDA Growth(294%)278%
EBIT Growth252%477%
Net Profit Growth288%15%
FCF Growth116%93%

Data powered by FactSet, Inc. and Morningstar, Inc.

Pyridam Farma Operational KPIs

Pyridam Farma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.

Access forward-looking KPIs for Pyridam Farma
Last FY202320242025202620272028
Revenue per Employee$0.1M---
Opex per Employee$0.0M---
S&M Expenses to Revenue6%17%7%6%
G&A Expenses to Revenue4%4%4%4%
R&D Expenses to Revenue1%3%1%1%
Opex to Revenue27%43%29%27%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Pyridam Farma Competitors

Pyridam Farma competitors include Hamlet BioPharma, Mersana Therapeutics, Satellos Bioscience, Orthocell, Molecular Partners, AN2 Therapeutics, Kotra Industries, Oramed Pharmaceuticals, Agenus and Vytrus Biotech.

Most Pyridam Farma public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Hamlet BioPharma--(30.0x)-
Mersana Therapeutics----
Satellos Bioscience--(2.9x)-
Orthocell19.0x12.8x(21.9x)(14.0x)
Molecular Partners-16.0x(0.7x)(0.7x)
AN2 Therapeutics--(1.6x)-
Kotra Industries2.3x2.5x8.3x9.3x
Oramed Pharmaceuticals41.2x41.2x1.1x-

This data is available for Pro users. Sign up to see all Pyridam Farma competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Pyridam Farma

When was Pyridam Farma founded?Pyridam Farma was founded in 1976.
Where is Pyridam Farma headquartered?Pyridam Farma is headquartered in Indonesia.
How many employees does Pyridam Farma have?As of today, Pyridam Farma has over 1K employees.
Is Pyridam Farma publicly listed?Yes, Pyridam Farma is a public company listed on Indonesia Stock Exchange.
What is the stock symbol of Pyridam Farma?Pyridam Farma trades under PYFA ticker.
When did Pyridam Farma go public?Pyridam Farma went public in 2001.
Who are competitors of Pyridam Farma?Pyridam Farma main competitors include Hamlet BioPharma, Mersana Therapeutics, Satellos Bioscience, Orthocell, Molecular Partners, AN2 Therapeutics, Kotra Industries, Oramed Pharmaceuticals, Agenus, Vytrus Biotech.
What is the current market cap of Pyridam Farma?Pyridam Farma's current market cap is $145M.
What is the current revenue of Pyridam Farma?Pyridam Farma's last fiscal year revenue is $155M.
What is the current EV/Revenue multiple of Pyridam Farma?Current revenue multiple of Pyridam Farma is 2.7x.
Is Pyridam Farma profitable?No, Pyridam Farma is not profitable.
How many companies Pyridam Farma has acquired to date?Pyridam Farma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Pyridam Farma has invested to date?Pyridam Farma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Pyridam Farma

Lists including Pyridam Farma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial